Osteosarcoma is the most common primary malignant neoplasm of bone in children, adolescents and young adults. Prior to 1970, the outcome for patients with osteosarcoma was dismal, with only 10-20 % of patients achieving long-term survival. The improvement in survival over the past four decades, now approaching 75 %, has largely been due to the addition of adjuvant chemotherapy to surgery.
Chemotherapy in Osteosarcoma Overview
Before the introduction of adjuvant systemic chemotherapy, patients with osteosarcoma had less than a 20 % OS. Most patients developed locally recurrent or metastatic disease, presumably from microscopic subclinical metastatic disease that was present at the time of diagnosis. 4 With modern multimodality therapy combining systemic chemotherapy and complete surgery, the cure rate now approaches over 70 % for patients with non-metastatic osteosarcoma. 5 Numerous trials have been performed in the past 30 years that have investigated the utility of adjuvant chemotherapy in patients with osteosarcoma. These trials have identified high-dose methotrexate (MTX), cisplatin, doxorubicin, ifosfamide and etoposide as active cytotoxic agents. [6] [7] [8] [9] [10] Combinations of these agents -although mostly empirical -now make up the cornerstone of treatment. Some of the notable trials using combination chemotherapy over the past 10 years are summarised in Table 1 . Although the exact combination, dose and schedule of chemotherapeutic agents is still debated, several randomised controlled trials have clearly demonstrated a significant survival benefit of systemic therapy in the management of osteosarcoma.
versus adjuvant chemotherapy in localised osteosarcoma. 15 Another rationale for using neoadjuvant chemotherapy is the capability of individualising therapy based on tumour response. It has been reported from numerous trials that histological response with tumour necrosis greater than 90 % confers a better prognosis. [15] [16] [17] [18] Intensifying Chemotherapy Based on Histological Response
The strategy of intensifying or altering post-operative therapy based on poor tumour necrosis was used successfully in the 1980s by investigators at the Memorial Sloan Kettering Cancer Center (T10 trial) and later confirmed by the Rizzoli Institute. 19, 20 However, the results of these trials
were not replicated in other large co-operative group studies. 17 Since then, the use of HDMTX has been intermittently subject to intense scrutiny. In general, the term HDMTX corresponds to a dose greater than 500 mg/m 2 . However, in osteosarcoma doses of 8-12 g/m 2 are used as standard, necessitating the use of leucovorin rescue to bypass the metabolic block induced by MTX. Interestingly, the rationale behind leucovorin rescuing normal over cancer cells is not totally understood. It is widely recognised that a peak serum MTX level of 750 μmol/mol or greater is a prerequisite to successful therapy and that inability to achieve this is associated with a poorer prognosis. 25 On the other hand, it has been reported in a smaller series that patients in whom a greater than 1,500 μmol/mol mean peak serum MTX concentration was achieved had a worse outcome. 26 Despite the absence of a randomised trial evaluating osteosarcoma treatment with and without HDMTX, it is generally acknowledged that it is 'time for final acceptance' of MTX in our standard osteosarcoma armamentarium. 27 The Addition of Ifosfamide Ifosfamide, the nitrogen mustard alkylating agent, is clearly an active agent either alone or in combination with etoposide in recurrent and/or metastatic osteosarcoma with a response rate of over 30 %. . 31 The standard use of MTP-PE alone or in combination with ifosfamide will likely be the subject of future confirmatory trials.
The dosing of ifosfamide has varied in these various clinical trials from 9 to 18 g/m 2 over three to five days. Clearly, higher doses of ifosfamide are associated with increased renal and haematological toxicities, although it is unknown whether higher doses of ifosfamide correlate with improved response rates and improved survival. When treating metastatic and/or recurrent disease, especially if having received ifosfamide in a previous regimen, we generally subscribe to the 'more is better' approach, using 14 g/m 2 .
Current Chemotherapeutic Regimen for Localised Osteosarcoma
There is no uniform chemotherapeutic regimen for osteosarcoma.
Generally we consider the three-drug regimen consisting of HDMTX 12 g/m 2 with leucovorin rescue, doxorubicin 75 mg/m 2 over 48 hours, and cisplatin 120 mg/m 2 over two days as standard therapy (see Table 2 ). The therapy given is identical to the standard arm 
Treatment of Osteosarcoma in Adults
Osteosarcoma is most common in adolescents, though a second incidence peak is noted in the seventh and eighth decades of life.
Many of these elderly cases are preceded by a previous malignancy with radiation therapy and Paget disease. 32 The survival of patients less than age 50 is similar to children, adolescents and young adults.
However, the OS is significantly decreased in older adults as less than 20 % of localised osteosarcoma patients in their sixties survive five years from diagnosis. 32 This is likely due to a combination of the biology of the tumour and diminished tolerance of chemotherapy from co-morbid conditions and end-organ damage. Generally, we advocate the use of the same regimen as used in our younger patients with very judicious surveillance of renal, hepatic and cardiac function.
In adults, as compared with adolescents, comparable rates of grade 4
toxicities have been noted with standard regimens as recently reported by the Rizzoli institute using HDMTX, cisplatin, doxorubicin and high-dose ifosfamide in osteosarcoma patients less than 40 years of age. However, delayed MTX excretion was associated with adults greater than 20 years old. This is likely from decreased renal function with older age. 33 HDMTX administration in patients greater than age 50 can be challenging and, if not tolerated, is often omitted, using doxorubicin and cisplatin as a standard combination. OS with omission of MTX seems to be similar.
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Chemotherapy in Recurrent and/or Metastatic Osteosarcoma
In contrast to the 60-70 % long-term survival of patients who present with localised osteosarcoma, patients with clinically evident metastatic disease at diagnosis have a poor prognosis. About 20 % of patients will present with metastatic osteosarcoma and the OS is reported to range from 10 to 40 %. 37, 38 There is no standard approach for treatment of patients with metastatic disease at diagnosis despite multiple clinical trials. Combination chemotherapy with doxorubicin, cisplatin, HDMTX, ifosfamide and etoposide is currently used at our institution for treatment. A POG trial with high-dose ifosfamide and etoposide induction therapy followed by adjuvant HDMTX, doxorubicin and cisplatin chemotherapy with lower-dose ifosfamide and etoposide had a 59 % overall response rate with a two-year projected survival of 39 % for lung-only and 58 % for bone-only involvement. 10 Although these results appear to be superior to historical controls, the long-term survival data have not yet been reported. In most studies, however, patients with bony metastases fared poorly versus those with pulmonary metastases, and survival appears to inversely correlate with the number of metastases. 37, 39 Notwithstanding that there is no standard for treatment of metastatic disease at diagnosis, we recommend aggressive multi-agent chemotherapy, primary local control and metastasectomy if possible. 51 Thirty to forty per cent of patients with localised osteosarcoma will Table 3 ).
Emerging Therapies
Over the past several decades, new chemotherapeutic agents have been added to the armamentarium of anticancer drugs. However, few new cytotoxic chemotherapeutic agents have shown activity or clinical benefit in osteosarcoma. The focus has been to develop targeted therapies for osteosarcoma to increase efficacy while minimising the bystander effects of our aggressive therapies.
Immunotherapy in Osteosarcoma
Immune approaches to osteosarcoma therapy continue to be investigated. Immunotherapy has been used in osteosarcoma therapy for several decades notably with the administration of IFN-α. 43 The effect of maintenance pegylated IFN-α is being studied in the Table 3 .
Bisphosphonates
Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate widely used in the prevention and treatment of osteoporosis and treatment of other disorders of bone metabolism. ZOL inhibits bone resorption and has also been commonly used to reduce skeletal complications from bone metastases in a variety of malignancies.
Additionally, it is recognised that ZOL has anti-neoplastic activity, the mechanisms of which are coming to light. Inhibiting the farnesyl pyrophosphate synthase enzyme in the mevalonate pathway causes changes in the post-translation modification of downstream G proteins (Ras, Rap1, Rho and Rab) and a subsequent decrease in cellular proliferation, adhesion and invasion. ZOL also appears to be a potent inhibitor of angiogenesis. 48 In osteosarcoma, preclinical data suggest a promising role for ZOL in therapy of both localised and metastatic lesions. In various mouse models, ZOL has been shown to inhibit osteoblastic and osteolytic components of osteosarcoma lesions 49 as well as reducing production of vascular endothelial growth factor (VEGF) and preventing lung metastases. 
Conclusions
The prognosis of localised osteosarcoma has improved dramatically over the past 30 years, with multimodality treatment of aggressive surgery and combination chemotherapy. There is no one standard chemotherapeutic regimen for osteosarcoma, though regimens with neoadjuvant HDMTX, doxorubicin and cisplatin, followed by definitive resection and then adjuvant chemotherapy with these aforementioned agents, is favoured by most centres. The addition of ifosfamide and etoposide is controversial, though they are clearly active in osteosarcoma. As such, the decision to use these agents for There are promising therapies emerging in trials and on the horizon, but a continued emphasis must be our understanding of the biology of osteosarcoma, with the goal of providing patients with new, molecularly targeted therapies. n
